Citigroup’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History
Bought
Maintained
Sold
Other funds holding LKFT
GS
TCM
MAP
PM
EC
DCM
Citigroup's LKFT Position: Q2 2026 in Review
Citigroup reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 29% in Q2 2026, selling an estimated $4.09K and leaving 354 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5238.
Citigroup first reported a position in LKFT in Q3 2015 and has held it in 34 quarters since. The position peaked at $20.6M in Q2 2020. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.
- Citigroup held 354 shares of Lakefront Biotherapeutics American Depositary Shares worth $10.6K as of Q2 2026.
- Citigroup sold 144 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $4.09K.
- Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5238 holding.
- Citigroup first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2015 and has held it in 34 quarters since.
- Citigroup's Lakefront Biotherapeutics American Depositary Shares position peaked at $20.6M in Q2 2020.
- 76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.